Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma
Status:
Active, not recruiting
Trial end date:
2023-06-23
Target enrollment:
Participant gender:
Summary
A single arm, open-label pilot study is designed to determine the safety, efficacy and
cytokinetics of CAR-BCMA T cells in patients with BCMA-positive refractory or relapsed
multiple myeloma.